Slide 1: Corporate Presentation May 2024
Exhibit 99.2 Corporate Presentation MAY 2024 © 2024 Cabaletta Bio. All rights reserved.
Slide 2: Disclaimer
Disclaimer The following presentation, including any printed or electronic copy of these slides, the talks given by the presenters, the information communicated during any delivery of the presentation and any question and answer session and any document or material distributed at or in connection wi
Slide 3: Develop and launch the first curative targeted cellular therapies for autoimmune diseases
Develop and launch the first curative targeted cellular therapies for patients with autoimmune diseases 3 3
Slide 4: Realizing the vision to transform autoimmune disease treatment
Realizing the vision to transform autoimmune disease treatment 2H24: Additional data 1H24: from myositis & No reported SLE trials CRS or ICANS in first myositis Initial clinical 2 or SLE patients data in SSc & gMG trials Designed & implemented novel Phase 1/2 clinical program to Clinical update acce
Slide 5: Pipeline targeting autoimmune diseases with high unmet need
Pipeline targeting autoimmune diseases with high unmet need Innovative and scalable clinical strategy with potential for accelerated development path Phase 1/2 Pivotal Program Trial Preclinical Dermatomyositis Rheumatology Anti-synthetase syndrome RESET-Myositis™ Neurology IMNM Dermatology Contains
Slide 6: Chimeric Antigen Receptor T Cells for Autoimmunity CABA-201
Chimeric Antigen Receptor T Cells for Autoimmunity CABA-201 6
Slide 7: Academic data: Immune system reset in autoimmune patients
Academic data: Immune system reset in autoimmune patients 1,2 Promising clinical responses in 15 patients across several autoimmune diseases with 4-1BB CD19-CAR T <7% 3-7 Rate of CRS more Months to naïve B severe than fever cell repopulation (1/15) 100% 2+ Years of SLE Objective clinical durable dru
Slide 8: CABA-201: CD19-CAR T specifically designed for autoimmunity
CABA-201 CABA-201: CD19-CAR T specifically designed for autoimmunity 1,2 3 Cabaletta’s CD19 binder with similar in vitro & in vivo activity to FMC63 (binder used in academic report ) No CRS or ICANS reported in either of the first myositis or SLE patients Clinical data reported by IASO using 4 licen
Slide 9: REstoring SElf-Tolerance (RESET) Phase 1/2 trials advancing
CABA-201 REstoring SElf-Tolerance (RESET™) Phase 1/2 trials advancing SLE & myositis trials currently enrolling, with a broadening portfolio to realize the potential of CABA-201 Phase 1/2 Trials Preclinical Rheum Myositis SLE SSc gMG 2024 Neuro Undiscl. > > > > Typical onset middle age Affects young
Slide 10: Clinical strategy to reduce risk, maximize reach & accelerate timelines
CABA-201 Clinical strategy to reduce risk, maximize reach & accelerate timelines Broad investigation of CABA-201 in well-defined patient populations with the same dose & similar design RESET-Myositis™ RESET-SLE™ RESET-SSc™ RESET-MG™ Lupus ASyS Skin + Organ AChR+ Nephritis Cohort Involvement gMG CABA
Slide 11: RESET-Myositis: Phase 1/2 study design for CABA-201
CABA-201 RESET-Myositis™: Phase 1/2 study design for CABA-201 Patient dosing commenced; enrolling patients with active myositis with DM, ASyS or IMNM subtypes Screening Phase 1/2 Study Design Study Objectives Open-label trial with parallel 6-subject cohorts Adults 18-65y Primary objective Safety & t
Slide 12: RESET-SLE: Phase 1/2 study design for CABA-201
CABA-201 RESET-SLE™: Phase 1/2 study design for CABA-201 Patient dosing commenced; enrolling patients with active SLE with or without renal involvement Screening Phase 1/2 Study Design Study Objectives Open-label trial with parallel 6-subject cohorts Adults 18-65y Primary objective Safety & tolerabi
Slide 13: Evaluating CABA-201 without preconditioning in pemphigus
CABA-201 Evaluating CABA-201 without preconditioning in pemphigus Elimination of preconditioning may expand CAR T Updated PV Study Design opportunity for autoimmune patients Open-label umbrella trial incorporating CABA-201 • Published data in multiple myeloma suggests into DSG3-CAART study 1 precond
Slide 14: Metrics to assess outcomes of B cell depletion in autoimmunity
Metrics to assess outcomes of B cell depletion in autoimmunity st For CABA-201, translational measures in 1 month may inform clinical outcomes at 3 months CAR T & 1 B cell levels CD19-CAR T Following treatment with autologous CD19-CAR T, 5 pts Cells with 14+ mo. of drug-free remission, as reported b
Slide 15: Manufacturing strategy
Manufacturing strategy Staged approach allows for efficient allocation of capital while leveraging experienced partners Early Phase: Late Phase & Commercial: Penn, CDMOs & CABA Process Scale-Up & Commercialization Data-gated, staged investment Ongoing • Penn has reliably provided timely product for
Slide 16: Securing & expanding our leadership in autoimmune cell therapy
Securing & expanding our leadership in autoimmune cell therapy Rapidly advancing to address patient need Broadening potential to serve patients Advancing the RESET™ clinical trials Biologic opportunity for potential cure or paradigm-shifting treatment with the goal of delivering on our commitment to
Slide 17: Corporate Summary
Corporate Summary Cabaletta Bio”
Slide 18: Cabaletta Bio leadership
Cabaletta Bio leadership Track record of operational success evaluating novel cell therapy candidates in autoimmunity LEADERSHIP TEAM Steven Nichtberger, M.D. Samik Basu, M.D. Gwendolyn Binder, Ph.D. David J. Chang, M.D., M.P.H., FACR Arun Das, M.D. President, CEO & Chairman Chief Scientific Officer
Slide 19: Realizing the vision to transform autoimmune disease treatment
Realizing the vision to transform autoimmune disease treatment 2H24: Additional data 1H24: from myositis & No reported SLE trials CRS or ICANS in first myositis Initial clinical 2 or SLE patients data in SSc & gMG trials Designed & implemented novel Phase 1/2 clinical program to Clinical update acce
Slide 20: © 2024 Cabaletta Bio. All rights reserved.
Corporate Presentation MAY 2024 © 2024 Cabaletta Bio. All rights reserved.